TRIB

Trinity Biotech

0.5677 USD
-0.0023
0.40%
Updated Apr 1, 2:49 PM EDT
1 day
-0.40%
5 days
-19.56%
1 month
-18.39%
3 months
-40.24%
6 months
-51.48%
Year to date
-40.24%
1 year
-70.89%
5 years
-88.10%
10 years
-99.41%
0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

21% more funds holding

Funds holding: 19 [Q3] → 23 (+4) [Q4]

0.46% less ownership

Funds ownership: 1.18% [Q3] → 0.72% (-0.46%) [Q4]

22% less capital invested

Capital invested by funds: $2.95M [Q3] → $2.3M (-$646K) [Q4]

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Research analyst outlook

We haven’t received any recent analyst ratings for TRIB.

Financial journalist opinion

Neutral
GlobeNewsWire
2 weeks ago
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement
DUBLIN, March 14, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice today from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that listed securities maintain a minimum bid price of US $1.00 per share, based on the closing bid price of the Company's American depositary shares (“ADSs”) for the last 30 consecutive business days. The Company also received notice today that the Company no longer meets the requirement in Nasdaq Listing Rule 5450(b) that listed securities maintain a minimum market value of publicly held shares (“MVPHS”) of US $15,000,000, based on Nasdaq's review of the Company's MVPHS for the last 30 consecutive business days.
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement
Neutral
GlobeNewsWire
2 weeks ago
Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process
DUBLIN and PORTLAND, Ore., March 13, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose monitoring (“CGM”) technology with the appointment of Barclays Capital Inc. (“Barclays”) as its exclusive financial advisor to support its ongoing strategic realignment, reflecting the Company's increased focus on its CGM technology as part of its broader transformation plan.
Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process
Neutral
GlobeNewsWire
1 month ago
Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company's Continuous Glucose Monitoring Technology
DUBLIN, Ireland, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has obtained an additional $4m in debt financing from its primary lender, Perceptive Advisors.
Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company's Continuous Glucose Monitoring Technology
Neutral
GlobeNewsWire
1 month ago
Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial
Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029
Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial
Neutral
GlobeNewsWire
2 months ago
Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology
Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029 Trinity Biotech's patented technology represents a paradigm shift in the global CGM market, projected to exceed $20 billion by 2029
Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology
Neutral
GlobeNewsWire
3 months ago
Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan
DUBLIN, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into amended agreements with its primary lender, Perceptive Advisors. These strategic amendments provide additional liquidity, further enhancing the Company's near-term financial position as it advances its Comprehensive Transformation Plan and continues development of its innovative continuous glucose monitoring (CGM) technology.
Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan
Neutral
GlobeNewsWire
3 months ago
Trinity Biotech Receives Early Approval from the World Health Organization to Begin Offshore Manufacturing of TrinScreen HIV & Uni-Gold HIV
DUBLIN, Ireland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced an important update on its Comprehensive Transformation Plan, which includes the transfer of manufacturing of both TrinScreen HIV and Uni-Gold HIV to a lower-cost offshore manufacturing partner. Trinity Biotech has received earlier than expected approval from the World Health Organization (WHO) to permit the later-stage manufacturing process of TrinScreen HIV and Uni-Gold HIV at its outsourced provider. This approval was a key prerequisite in the manufacturing transfer the Company has been working towards as part of its Comprehensive Transformation Plan.
Trinity Biotech Receives Early Approval from the World Health Organization to Begin Offshore Manufacturing of TrinScreen HIV & Uni-Gold HIV
Neutral
Seeking Alpha
4 months ago
Trinity Biotech Plc (TRIB) Q3 2024 Earnings Call Transcript
Trinity Biotech Plc (NASDAQ:TRIB ) Q3 2024 Earnings Conference Call November 15, 2024 10:00 AM ET Company Participants Eric Ribner - Investor Relations John Gillard – President, Chief Executive Officer Louise Tallon - Chief Financial Officer Conference Call Participants James Sidoti - Sidoti & Company Paul Nouri – Noble Equity Funds Operator Greetings. Welcome to the Trinity Biotech Third Quarter 2024 Earnings Conference Call.
Trinity Biotech Plc (TRIB) Q3 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
4 months ago
Trinity Biotech Announces Q3 2024 Financial Results
Q3 2024 total revenue of $15.2 million grew +3% Y/Y based on strong demand and output in the TrinScreen HIV business Point-of-Care product revenue of $4.3 million grew 60% Y/Y Reiterates guidance to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized run-rate revenues of approximately $75 million by Q2 2025 Reiterates guidance to achieve 2024 sales revenue for TrinScreen HIV of approximately $10 million DUBLIN, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the Company's results for the quarter ended September 30, 2024. Key Highlights and Developments Continued Revenue and Profitability Improvements Year-over-year revenue growth of 3% and continued disciplined execution on our profitability enhancing initiatives contributed to a decrease in the operating loss (before restructuring and impairment charges) to $2.2 million from $4.5m in Q3 2023, a 51% improvement.
Trinity Biotech Announces Q3 2024 Financial Results
Neutral
GlobeNewsWire
4 months ago
Trinity Biotech to Announce Q3 2024 Financial Results
Conference Call Scheduled for Friday, November 15, 2024 at 10:00 AM ET Conference Call Scheduled for Friday, November 15, 2024 at 10:00 AM ET
Trinity Biotech to Announce Q3 2024 Financial Results
Charts implemented using Lightweight Charts™